Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2021

Moon CS, Reglero C, Cortes JR, S Quinn A, Alvarez S, Zhao J, et al. induces NF-κB signaling-driven peripheral T cell lymphoma. Nat Cancer. 2021;2(1):98-113.

Leo P, Janowczyk A, Elliott R, Janaki N, Bera K, Shiradkar R, et al. Computer extracted gland features from H&E predicts prostate cancer recurrence comparably to a genomic companion diagnostic test: a large multi-site study. NPJ Precis Oncol. 2021;5(1):35.

Naidoo M, Levine F, Gillot T, Orunmuyi AT, E Olapade-Olaopa O, Ali T, et al. MicroRNA-1205 Regulation of FRYL in Prostate Cancer. Front Cell Dev Biol. 2021;9:647485.

Park HJ, Baek I, Cheang G, Solomon JP, Song W. Comparison of RNA-Based Next-Generation Sequencing Assays for the Detection of NTRK Gene Fusions. J Mol Diagn. 2021;23(11):1443-1451.

Manohar J, Abedian S, Martini R, Kulm S, Salvatore M, Ho K, et al. Social and Clinical Determinants of COVID-19 Outcomes: Modeling Real-World Data from a Pandemic Epicenter. medRxiv. 2021.

Slaughter MJ, Shanle EK, Khan A, Chua KF, Hong T, Boxer LD, et al. HDAC inhibition results in widespread alteration of the histone acetylation landscape and BRD4 targeting to gene bodies. Cell Rep. 2021;34(3):108638.

Castrodad-Rodríguez CA, Choudhuri J, El-Jabbour T, Cheng J, Westerhoff M, Panarelli NC. Clinical significance of pathologic abnormalities in biopsy samples from the appendiceal orifice. Histopathology. 2021;79(5):751-757.

Advani RH, Skrypets T, Civallero M, Spinner MA, Manni M, Kim WS, et al. Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T-cell Project. Blood. 2021;138(3):213-220.

Fangazio M, Ladewig E, Gomez K, Garcia-Ibanez L, Kumar R, Teruya-Feldstein J, et al. Genetic mechanisms of HLA-I loss and immune escape in diffuse large B cell lymphoma. Proc Natl Acad Sci U S A. 2021;118(22).

Pikman Y, Tasian SK, Sulis ML, Stevenson K, Blonquist TM, Winger BA, et al. Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory, or High-Risk Leukemias: A Report from the LEAP Consortium. Cancer Discov. 2021;11(6):1424-1439.